Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
The gloom deepens for biopharma stocks
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
Intellia delivers a second knockdown success
Encouraging early results in hereditary angioedema join further progress in amyloidosis, but investors remain wary.
Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
